Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Sperm DNA Integrity is Unaffected by Thiopurine Treatment in Men With Inflammatory Bowel Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Long-term Risk of Cancer Following Ileal Pouch-anal Anastomosis for Ulcerative Colitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A role for thiopurine metabolites in the synergism between thiopurines and infliximab in inflammatory bowel disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Temporal Evolution of Histological Abnormalities in Microscopic Colitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pattern recognition receptor polymorphisms in early periodontitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Lewis and AB0 blood group-phenotypes in periodontitis, cardiovascular disease, obesity and stroke

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Casper Steenholdt
  • Klaus Bendtzen
  • Jørn Brynskov
  • Ole Ø Thomsen
  • Lars K Munck
  • Lisbet A Christensen
  • Gitte Pedersen
  • Jens Kjeldsen
  • Mark A Ainsworth
View graph of relations

BACKGROUND AND AIMS: Intensification of the infliximab (IFX) regimen is recommended if the treatment effect is inadequate. However, the rationale for this is not well defined as the underlying mechanisms vary. The aim of this study was to explore the association between changes in serum IFX and anti-IFX antibodies (Abs) after IFX intensification and clinical outcomes.

METHODS: We performed a post hoc analysis of a randomized clinical trial including 42 Crohn's disease patients with IFX treatment failure, all treated with an intensified IFX regimen (5mg/kg every 4 week) for 12 weeks. Trough serum IFX and anti-IFX Ab concentrations were measured by a homogeneous mobility shift binding assay (HMSA) and a functional cell-based reporter gene assay (RGA) at treatment failure and the end of the trial.

RESULTS: Twenty-one patients (50%) regained clinical response on the intensified IFX regimen. The increase in serum trough levels of IFX during treatment intensification was higher among responders than non-responders (RGA, 8.8 versus 3.0 μg/mL, p = 0.035; HMSA, 9.9 versus 4.7 μg/mL, p = 0.040), and differentiated patients by clinical outcome (RGA, area under receiver operating characteristic curve [AUC] 0.75 [0.53-0.97], p = 0.035; HMSA, AUC 0.74 [0.53-0.95], p = 0.042). All responders exhibited an IFX increase ≥2.6 μg/mL (sensitivity 100%, specificity 50%). Anti-IFX Abs detected by HMSA in 13 patients (32%) were often non-functional and became undetectable during IFX intensification. However, even functional anti-IFX Abs detected by RGA in six patients (15%) became undetectable.

CONCLUSION: Increase in IFX levels following treatment intensification was associated with improved clinical outcomes, indicating insufficient drug levels in a subgroup of patients. Anti-IFX Abs may become undetectable during treatment intensification, suggesting lowered production or the formation of immune complexes.

Original languageEnglish
JournalJournal of Crohn's & colitis
Volume9
Issue number3
Pages (from-to)238-45
Number of pages8
ISSN1873-9946
DOIs
Publication statusPublished - Mar 2015

    Research areas

  • Adolescent, Adult, Antibodies, Crohn Disease, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Monitoring, Female, Gastrointestinal Agents, Humans, Infliximab, Linear Models, Male, Prospective Studies, ROC Curve, Treatment Failure, Young Adult

ID: 45996129